-
Something wrong with this record ?
Bone metabolism parameters and their relation to cytogenetics in multiple myeloma
P. Krhovska, T. Pika, J. Proskova, J. Balcarkova, J. Zapletalova, J. Bacovsky, J. Minarik
Language English Country Great Britain
Document type Journal Article
Grant support
00098892
MZ ČR - RVO
IGA-LF-2020-002
MZ ČR - RVO
PubMed
35306691
DOI
10.1111/ejh.13771
Knihovny.cz E-resources
- MeSH
- Biomarkers MeSH
- Cytogenetic Analysis MeSH
- Bone Marrow metabolism MeSH
- Humans MeSH
- Multiple Myeloma * diagnosis genetics MeSH
- Tumor Microenvironment MeSH
- Vascular Endothelial Growth Factor A MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: Our aim was to correlate serum levels of selected markers of bone metabolism and bone marrow microenvironment to cytogenetic changes in patients with multiple myeloma (MM). METHODS: We assed cytogenetic changes in 308 patients and correlated them with the following levels of bone marrow metabolism: thymidine kinase (TK), β2-microglobulin (b-2-m), Dickkopf-1 protein (DKK-1), C-terminal telopeptide collagen-I (ICTP), N-terminal propeptide of type I procollagen (PINP), receptor for interleukin 6 (rIL-6), vascular cell adhesive molecule-1 (VCAM), soluble intercellular adhesion molecule-1, osteoprotegerin (OPG), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), syndecan-1 (SYN-1) and Fas antigen. RESULT: Individuals with delRB1 had lower levels of OPG (M = 7.39 vs. 5.46 pmol/L, p = .025) and VEGF (M = 304 vs. 196 pg/ml; p = .036). t(14;16) was associated with higher β2m levels (M = 7.59 vs. 4.13 mg/L; p = .022) and lower DKK-1 levels (M = 4465 ng/L vs. 12,593). The presence of 1q21 gain was associated with higher levels of TK (M = 100.0 vs. 11.0 IU/L, p = .026) and lower levels of PINP (M = 49.3 vs. 67.4 mg/L, p = .030). CONCLUSIONS: Our analysis has shown, some cytogenetic changes, especially delRB1, t(14;16) and 1q21gain, which affect the components of the cytokine network in multiple myeloma.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017883
- 003
- CZ-PrNML
- 005
- 20220804134436.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/ejh.13771 $2 doi
- 035 __
- $a (PubMed)35306691
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Krhovska, Petra $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000179007624 $7 xx0214569
- 245 10
- $a Bone metabolism parameters and their relation to cytogenetics in multiple myeloma / $c P. Krhovska, T. Pika, J. Proskova, J. Balcarkova, J. Zapletalova, J. Bacovsky, J. Minarik
- 520 9_
- $a OBJECTIVES: Our aim was to correlate serum levels of selected markers of bone metabolism and bone marrow microenvironment to cytogenetic changes in patients with multiple myeloma (MM). METHODS: We assed cytogenetic changes in 308 patients and correlated them with the following levels of bone marrow metabolism: thymidine kinase (TK), β2-microglobulin (b-2-m), Dickkopf-1 protein (DKK-1), C-terminal telopeptide collagen-I (ICTP), N-terminal propeptide of type I procollagen (PINP), receptor for interleukin 6 (rIL-6), vascular cell adhesive molecule-1 (VCAM), soluble intercellular adhesion molecule-1, osteoprotegerin (OPG), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), syndecan-1 (SYN-1) and Fas antigen. RESULT: Individuals with delRB1 had lower levels of OPG (M = 7.39 vs. 5.46 pmol/L, p = .025) and VEGF (M = 304 vs. 196 pg/ml; p = .036). t(14;16) was associated with higher β2m levels (M = 7.59 vs. 4.13 mg/L; p = .022) and lower DKK-1 levels (M = 4465 ng/L vs. 12,593). The presence of 1q21 gain was associated with higher levels of TK (M = 100.0 vs. 11.0 IU/L, p = .026) and lower levels of PINP (M = 49.3 vs. 67.4 mg/L, p = .030). CONCLUSIONS: Our analysis has shown, some cytogenetic changes, especially delRB1, t(14;16) and 1q21gain, which affect the components of the cytokine network in multiple myeloma.
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a kostní dřeň $x metabolismus $7 D001853
- 650 _2
- $a cytogenetické vyšetření $7 D020732
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x diagnóza $x genetika $7 D009101
- 650 _2
- $a nádorové mikroprostředí $7 D059016
- 650 _2
- $a vaskulární endoteliální růstový faktor A $7 D042461
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pika, Tomas $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Proskova, Jitka $u Department of Clinical Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Balcarkova, Jana $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Zapletalova, Jana $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Bacovsky, Jaroslav $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Minarik, Jiri $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
- 773 0_
- $w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 109, č. 1 (2022), s. 75-82
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35306691 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134430 $b ABA008
- 999 __
- $a ok $b bmc $g 1821804 $s 1169126
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 109 $c 1 $d 75-82 $e 20220324 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
- GRA __
- $a 00098892 $p MZ ČR - RVO
- GRA __
- $a IGA-LF-2020-002 $p MZ ČR - RVO
- LZP __
- $a Pubmed-20220720